Microparticles and Exosomes in Gynecologic Neoplasias

 

 Buy Article Permissions and Reprints

ABSTRACT

This review presents an overview of the functions of microparticles and exosomes in gynecologic neoplasias. Growing evidence suggests that vesicles released from cancer cells in gynecologic malignancies contribute to the hypercoagulable state of these patients and contribute to tumor progression by suppressing the immune system, facilitating extracellular matrix degradation and removal of cytostatics from the tumor cell. Exosomes from ovarian carcinoma cells were shown to be present in peripheral blood and to augment tumor growth, suggesting that these vesicles directly support growth of tumor cells.

REFERENCES

• 1 Toth B, Lok C A, Böing A et al. Microparticles and exosomes: impact on normal and complicated pregnancy.  Am J Reprod Immunol. 2007;  58(5) 389-402
  CrossrefPubMedGoogle Scholar
• 2 Dvorak H F, Quay S C, Orenstein N S et al. Tumor shedding and coagulation.  Science. 1981;  212(4497) 923-924
  CrossrefPubMedGoogle Scholar
• 3 Dvorak H F, Van DeWater L, Bitzer A M et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells.  Cancer Res. 1983;  43(9) 4434-4442
  PubMedGoogle Scholar
• 4 Kakkar A K, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson R C. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor.  Lancet. 1995;  346(8981) 1004-1005
  CrossrefPubMedGoogle Scholar
• 5 Goyal D, Choudhury A, Lip G Y. Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies.  Curr Opin Obstet Gynecol. 2005;  17(1) 13-20
  PubMedGoogle Scholar
• 6 Satoh T, Matsumoto K, Uno K et al. Silent venous thromboembolism before treatment in endometrial cancer and the risk factors.  Br J Cancer. 2008;  99(7) 1034-1039
  CrossrefPubMedGoogle Scholar
• 7 Uno K, Homma S, Satoh T et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.  Br J Cancer. 2007;  96(2) 290-295
  CrossrefPubMedGoogle Scholar
• 8 Tesselaar M E, Romijn F P, Van Der Linden I K, Prins F A, Bertina R M, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.  J Thromb Haemost. 2007;  5(3) 520-527
  CrossrefPubMedGoogle Scholar
• 9 Yokota N, Koizume S, Miyagi E et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells.  Br J Cancer. 2009;  101(12) 2023-2029
  CrossrefPubMedGoogle Scholar
• 10 Keller S, König A K, Marmé F et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.  Cancer Lett. 2009;  278(1) 73-81
  CrossrefPubMedGoogle Scholar
• 11 Liu C, Yu S, Zinn K et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.  J Immunol. 2006;  176(3) 1375-1385
  PubMedGoogle Scholar
• 12 Dolo V, Pizzurro P, Ginestra A, Vittorelli M L. Inhibitory effects of vesicles shed by human breast carcinoma cells on lymphocyte 3H-thymidine incorporation, are neutralised by anti TGF-beta antibodies.  J Submicrosc Cytol Pathol. 1995;  27(4) 535-541
  PubMedGoogle Scholar
• 13 Abrahams V M, Straszewski S L, Kamsteeg M et al. Epithelial ovarian cancer cells secrete functional Fas ligand.  Cancer Res. 2003;  63(17) 5573-5581
  PubMedGoogle Scholar
• 14 Frängsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level.  Mol Hum Reprod. 2005;  11(1) 35-41
  CrossrefPubMedGoogle Scholar
• 15 Taylor D D, Akyol S, Gercel-Taylor C. Pregnancy-associated exosomes and their modulation of T cell signaling.  J Immunol. 2006;  176(3) 1534-1542
  CrossrefPubMedGoogle Scholar
• 16 Martin L P, Schilder R J. Management of recurrent ovarian carcinoma: current status and future directions.  Semin Oncol. 2009;  36(2) 112-125
  CrossrefPubMedGoogle Scholar
• 17 Hamilton K K, Hattori R, Esmon C T, Sims P J. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.  J Biol Chem. 1990;  265(7) 3809-3814
  PubMedGoogle Scholar
• 18 Safaei R, Larson B J, Cheng T C et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells.  Mol Cancer Ther. 2005;  4(10) 1595-1604
  CrossrefPubMedGoogle Scholar
• 19 Dolo V, D'Ascenzo S, Violini S et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro.  Clin Exp Metastasis. 1999;  17(2) 131-140
  CrossrefPubMedGoogle Scholar
• 20 Graves L E, Ariztia E V, Navari J R, Matzel H J, Stack M S, Fishman D A. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.  Cancer Res. 2004;  64(19) 7045-7049
  CrossrefPubMedGoogle Scholar
• 21 Runz S, Keller S, Rupp C et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.  Gynecol Oncol. 2007;  107(3) 563-571
  CrossrefPubMedGoogle Scholar
• 22 Dolo V, Ginestra A, Ghersi G, Nagase H, Vittorelli M L. Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities.  J Submicrosc Cytol Pathol. 1994;  26(2) 173-180
  PubMedGoogle Scholar
• 23 Ginestra A, Miceli D, Dolo V, Romano F M, Vittorelli M L. Membrane vesicles in ovarian cancer fluids: a new potential marker.  Anticancer Res. 1999;  19(4C) 3439-3445
  PubMedGoogle Scholar
• 24 Stoeck A, Keller S, Riedle S et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44.  Biochem J. 2006;  393(Pt 3) 609-618
  CrossrefPubMedGoogle Scholar
• 25 Gutwein P, Stoeck A, Riedle S et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells.  Clin Cancer Res. 2005;  11(7) 2492-2501
  CrossrefPubMedGoogle Scholar
• 26 Taylor D D, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.  Gynecol Oncol. 2008;  110(1) 13-21
  CrossrefPubMedGoogle Scholar
• 27 Taylor D D, Gercel-Taylor C, Parker L P. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.  Gynecol Oncol. 2009;  115(1) 112-120
  CrossrefPubMedGoogle Scholar
• 28 Li J, Sherman-Baust C A, Tsai-Turton M, Bristow R E, Roden R B, Morin P J. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer.  BMC Cancer. 2009;  9 244
  CrossrefPubMedGoogle Scholar
• 29 Ochieng J, Pratap S, Khatua A K, Sakwe A M. Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes.  Exp Cell Res. 2009;  315(11) 1875-1888
  CrossrefPubMedGoogle Scholar
• 30 Al-Nedawi K, Meehan B, Micallef J et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.  Nat Cell Biol. 2008;  10(5) 619-624
  CrossrefPubMedGoogle Scholar
• 31 Skog J, Würdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.  Nat Cell Biol. 2008;  10(12) 1470-1476
  CrossrefPubMedGoogle Scholar

Rienk NieuwlandPh.D. 

Department of Clinical Chemistry, Academic Medical Center, Meibergdreef 9

1100 AZ Amsterdam, The Netherlands

Email: r.nieuwland@amc.nl